Cargando…
Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited
PURPOSE: Whole Exome Sequencing (WES) is being adopted for neurodevelopmental disorders in pediatric patients. However, little is known about current coverage policies or the evidence cited supporting these policies. Our study is the first in-depth review of private payer WES coverage policies for p...
Autores principales: | Douglas, Michael P., Parker, Stephanie L., Trosman, Julia R., Slavotinek, Anne M., Phillips, Kathryn A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329652/ https://www.ncbi.nlm.nih.gov/pubmed/29997388 http://dx.doi.org/10.1038/s41436-018-0043-3 |
Ejemplares similares
-
Private Payer Coverage Policies for ApoE-e4 Genetic Testing
por: Arias, Jalayne J., et al.
Publicado: (2021) -
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018) -
Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016) -
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients
por: Menzel, Michael, et al.
Publicado: (2023) -
Identifying the genetic causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome sequencing (WES)
por: Leung, Gordon K C, et al.
Publicado: (2018)